Versigent PLC VGNT
42.46 USD -0.43 (-1.00%)
At closeNov 12, 2026, 4:00 PM EST
42.46 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
41.93 Day range 43.00
26.34 52-week range 50.89
- YTD
- +40.60%
- 1 year
- +40.60%
News
marketbeat.com Versigent Q3 Earnings Call Highlights Versigent NYSE: VGNT raised its full-year free cash flow outlook and narrowed its earnings forecast after reporting higher third-quarter sales and adjusted earnings, even as global automotive…
benzinga.com TD Cowen Maintains Buy on Versigent, Raises Price Target to $59 TD Cowen analyst Itay Michaeli maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $58 to $59.
benzinga.com RBC Capital Maintains Outperform on Versigent, Lowers Price Target to $52 RBC Capital analyst Tom Narayan maintains Versigent (NYSE:VGNT) with a Outperform and lowers the price target from $53 to $52.
benzinga.com BNP Paribas Reiterates Outperform on Versigent, Lowers Price Target to $54 BNP Paribas analyst James Picariello reiterates Versigent (NYSE:VGNT) with a Outperform and lowers the price target from $55 to $54.
businesswire.com Versigent CFO to Participate in RBC Capital Markets Global Industrials Conference on November 17 SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Versigent PLC (NYSE: VGNT), a global leader in the design and manufacture of low- and high-voltage electrical architectures, today announced Chief…
benzinga.com Versigent Raises FY2026 Sales Guidance from $9.400B-$9.600B to $9.500B-$9.600B vs $9.516B Est Versigent (NYSE:VGNT) raises FY2026 sales outlook from $9.400 billion-$9.600 billion to $9.500 billion-$9.600 billion vs $9.516 billion estimate.- benzinga.com Versigent Q3 Adj. EPS $1.91 Beats $1.80 Estimate, Sales $2.450B Beat $2.422B Estimate Versigent (NYSE:VGNT) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $1.80 by 6.11 percent. The company reported quarterly sales of $2.450 billion which…
benzinga.com 10 Consumer Discretionary Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com RBC Capital Maintains Outperform on Versigent, Raises Price Target to $53 RBC Capital analyst Tom Narayan maintains Versigent (NYSE:VGNT) with a Outperform and raises the price target from $52 to $53.
benzinga.com Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58 Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.
benzinga.com Versigent Q2 2026 Earnings Call Transcript Versigent (NYSE:VGNT) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call…
benzinga.com David Einhorn Has 7 New Stock Picks: Hedge Fund Manager Bets on Buyouts, Spinoffs A hedge fund is betting on spinoffs and buyouts for several of its new portfolio holdings.
benzinga.com Argus Research Maintains Buy on Versigent, Raises Price Target to $54 Argus Research analyst Bill Selesky maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $50 to $54.- benzinga.com Evercore ISI Group Maintains Outperform on Versigent, Raises Price Target to $65 Evercore ISI Group analyst Chris McNally maintains Versigent (NYSE:VGNT) with a Outperform and raises the price target from $60 to $65.
- benzinga.com TD Cowen Maintains Buy on Versigent, Raises Price Target to $58 TD Cowen analyst Itay Michaeli maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $49 to $58.
benzinga.com RBC Capital Upgrades Versigent to Outperform, Raises Price Target to $52 RBC Capital analyst Tom Narayan upgrades Versigent (NYSE:VGNT) from Sector Perform to Outperform and raises the price target from $41 to $52.- benzinga.com Wells Fargo Maintains Overweight on Versigent, Raises Price Target to $56 Wells Fargo analyst Colin Langan maintains Versigent (NYSE:VGNT) with a Overweight and raises the price target from $48 to $56.
- benzinga.com Versigent Q2 EPS $1.92 Beats $1.35 Estimate, Sales $2.444B Beat $2.313B Estimate Versigent (NYSE:VGNT) reported quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.35 by 42.22 percent. The company reported quarterly sales of $2.444 billion which…
- benzinga.com CORRECTION: Versigent Raises FY2026 Sales Guidance from $9.100B-$9.400B to $9.400B-$9.600B vs $9.286B Est Versigent (NYSE:VGNT) raises FY2026 sales outlook from $9.100 billion-$9.400 billion to $9.400 billion-$9.600 billion vs $9.286 billion estimate.
- benzinga.com Goldman Sachs Initiates Coverage On Versigent with Buy Rating, Announces Price Target of $48 Goldman Sachs analyst Mark Delaney initiates coverage on Versigent (NYSE:VGNT) with a Buy rating and announces Price Target of $48.
- benzinga.com RBC Capital Maintains Sector Perform on Versigent, Raises Price Target to $41 RBC Capital analyst Tom Narayan maintains Versigent (NYSE:VGNT) with a Sector Perform and raises the price target from $34 to $41.
- benzinga.com Wells Fargo Maintains Overweight on Versigent, Raises Price Target to $48 Wells Fargo analyst Colin Langan maintains Versigent (NYSE:VGNT) with a Overweight and raises the price target from $42 to $48.
benzinga.com S&P 500, Nasdaq 100 Drop From Records As Rate-Hike Bets Build, Oil Climbs: Stock Market Today U.S. stocks retreated from record highs at midday Wednesday as hotter-than-expected economic data and a renewed surge in Treasury yields revived fears the Federal Reserve could soon raise interest…- benzinga.com TD Cowen Maintains Buy on Versigent, Raises Price Target to $49 TD Cowen analyst Itay Michaeli maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $47 to $49.
- benzinga.com Wells Fargo Maintains Overweight on Versigent, Raises Price Target to $42 Wells Fargo analyst Colin Langan maintains Versigent (NYSE:VGNT) with a Overweight and raises the price target from $35 to $42.
- benzinga.com Versigent Q1 Sales $2.212B Up From $2.024B YoY Versigent (NYSE:VGNT) reported $2.212 billion in sales this quarter. This is a 9.29 percent increase over sales of $2.024 billion the same period last year.
benzinga.com This Micron Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlooks on top stocks. Check out our analyst ratings page for upgrades, downgrades, and initiations.- benzinga.com Deutsche Bank Initiates Coverage On Versigent with Hold Rating, Announces Price Target of $35 Deutsche Bank analyst Edison Yu initiates coverage on Versigent (NYSE:VGNT) with a Hold rating and announces Price Target of $35.
benzinga.com 10 Consumer Discretionary Stocks With Whale Alerts In Today's Session - benzinga.com UBS Initiates Coverage On Versigent with Buy Rating, Announces Price Target of $43 UBS analyst Joseph Spak initiates coverage on Versigent (NYSE:VGNT) with a Buy rating and announces Price Target of $43.
benzinga.com Oil Trim Gains, Stocks Rebound On Lebanon-Israel Talks: What's Moving Markets Thursday? U.S. stocks held modest midday gains Thursday as tentative Lebanon–Israel diplomatic overtures introduced a fragile layer of optimism into an otherwise tense geopolitical backdrop.
benzinga.com This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street analysts have changed outlooks on top stocks. For details on changes, check out analyst ratings page. See what analysts think of AVTX.- benzinga.com Wells Fargo Initiates Coverage On Versigent with Overweight Rating, Announces Price Target of $35 Wells Fargo analyst Colin Langan initiates coverage on Versigent (NYSE:VGNT) with a Overweight rating and announces Price Target of $35.
benzinga.com Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.